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Abstract
The human endogenous retroviruses HERV-K HML-2 have been considered a possible cause of human breast
cancer (BrC). A HERV-K HML-2 fully intact provirus Xq21.33 was recently identified in some West African people. We
used PCR technology to search for the Xq21.33 provirus in DNA from Nigerian women with BrC and controls. to
see if Xq21.33 plays any role in predisposing to BrC. This provirus was detected in 27 of 216 (12.5%) women with
BrC and in 22 of 219 (10.0%) controls. These results were not statistically significant. The prevalence of provirus in
premenopausal control women 44 years or younger [18/157 (11.46%)} vs women with BrC [12/117 (10.26%)]
showed no statistical difference. The prevalence of virus in postmenopausal control women > 45 yrs. was 7.4%
(4/54) vs 15.31% (15/98) in postmenopausal women with BrC. These changes were not statistically significant at
<.05, but the actual p value of <.0.079, suggests that Xq21.33 might play some role in predisposing to BrC in
postmenopausal women. Provirus was present in Ghanaian women (6/87), in 1/6 Pygmy populations and in African
American men (4/45) and women (6/68), but not in any Caucasian women (0/109). Two BrC cell lines (HCC 70 and
DT22) from African American women had Xq21.33. Env regions of the virus which differed by 2–3 SNPs did not
alter the protein sequence of the virus. SNP at 5730 and 8529 were seen in all persons with provirus, while 54%
had an additional SNP at 7596.Two Nigerian women and 2 Ghanaian women had additional unusual SNPs.
Homozygosity was seen in (5/27) BrC and (2/22) control women. The genetic variation and homozygosity patterns
suggested that there was gene conversion of this X chromosome associated virus. The suggestive finding in this
preliminary data of possible increased prevalence of Xq21.33 provirus in post-menopausal Nigerian women with
BrC should be clarified by a more statistically powered study sample to see if postmenopausal African and/or
African American women carriers of Xq21.33 might show increased risk of BrC. The implication of finding such a
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link would be the development of antiretroviral drugs that might aid in preventing BrC in Xq21.33+ women.
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Background
Much is lacking in our understanding of the causes of
human breast cancer (BrC). There is some evidence that
a mouse mammary tumor virus (MMTV) may be associ-
ated with, and be a cause of some human BrC. Such a
virus is often called human mammary tumor virus
(HMTV). The biology of MMTV has been summarized
by Dudley et al. [1] with much speculation about how
MMTV might relate to the development of BrC in
humans. Numerous studies over the last 40 years have
been extensively reviewed by Amarante et al. [2]. To
date, MMTV does not appear to be causative of human
BrC. As an animal model, it is clear that, at least in the
mouse, this virus depends on breast feeding for trans-
mission. It produces cancer later in the age of the
mouse, and it does not carry any oncogenes, but de-
pends on its insertion site near growth factors in the
mouse genome to be able produce BrC [1, 2].
The human endogenous retroviruses HERV-K HML-2
have also been implicated as having some role in the
pathogenesis of BrC as discussed below. These retrovi-
ruses began to enter the evolving primate genome over
35,000,000 years ago (MYA) through infection, integrat-
ing in the genome of oocyte or spermatocyte cells. After
fertilization, offspring of these infected animals now con-
tained a provirus in every cell. If animals survived this
infection they could pass this provirus from generation
to generation [3]. With continued evolution, subsequent
infections occurred in such animals from uncertain
sources, perhaps from other locally infected simians,
rodents, and later in evolution from man. These newly
acquired viruses could again enter into an ovary or
spermatocyte and reinfect the genome in a different gen-
omic location [4–14]. Many of these viruses entered the
human genome “after the hominid-chimpanzee split 6
million years ago (MYA)” [6, 7]. These proviruses are
divided into type 1, which have a 292 bp deletion in the
env gene, and type 2, which have a more complete env
gene. With time, most of these proviruses developed
lethal mutations and indels which prevented any subse-
quent activation of infectious virus in the host. In
addition, as these viruses had identical long terminal
repeats (LTRs) on both the 5′ and 3′ side of the virus at
the time of integration, through homologous recombin-
ation during cell replication some of these integrated
viruses deleted all internal genes but solo LTRs which
have remained in many thousand genomic locations in
the hominid genome.
Much work has been done recently to fully detail the
total number of HERV-K HML-2 proviruses in the hu-
man genome. Most of these proviruses are in all
humans, but some have arisen in limited areas of the
world and in limited populations, occurring at different
times in evolution with variable spread throughout the
world. Proviruses are now classified by their location in
the chromosomal arm of the human genome. It is esti-
mated that 117 of these proviruses remain in the human
genome with several thousands of solo LTRs [6, 7, 9,
14–20]. Recently some 80 to 90 proviruses, called K222
were discovered which are mostly in the pericentromere
of chromosomes 13, 14 and 15 [21]. In addition up to a
few 1000 HERV-K HML-2 proviruses were found, called
K111 [22–24], which exist mostly in the pericentromeric
area primarily in chromosome 21 and 22. While the
chromosomal proviruses entered the genome through ei-
ther exogenous infection or endogenous reinfection,
K111 and K222 probably entered the pericentromere
and peripheral centromeric area first by infection. Later
they appear to have spread extensively and rapidly in
modern man by homologous recombination throughout
these areas of repetitive elements.
Almost all of the currently known HERV-K HML-2
proviruses do not have fully functional viral genes. How-
ever 3 proviruses, K113 (19p13.11), K115 (8p23.1) and a
recently discovered provirus Xq21.33 appear to have in-
tact gag, prot, pol and env genes [25–32]. K113 and
K115 are not in all humans, and their distribution varies
across the world. K113 is felt to have arisen in Africa,
but is present in disparate populations. In Poland, as an
example, the frequency of K113 is 11.8 and for K115 it
is 7.9% [32]. In a cohort of women with BrC K113 was
in 16.7% and K115 was in 4.9% [27] of women tested. In
Sub-Saharan Africa K113 was found in 21.8% and K115
in 34.1% [28] of patients with BrC. In the 1000 Genomes
Project (1KGP) database K113 was found in 27% of all
samples and 52% of samples of African origin [31]. K113
is estimated to have arisen in the human genome about
0.8MYA while K115 arose about 1.0MYA [28]. K113 ap-
pears to be able to make intact viral particles when
inserted in a baculovirus expression system and is
expressed in insect cells, but these lacked functional pro-
tease or reverse transcriptase activity [26]. Similarly,
when K113 was cloned into a modified pBluescript vec-
tor, while some viral proteins could be made, there was
“inefficient particle formation, impaired synthesis of the
Gag-Pro-Po precursor and a lack of envelope protein
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incorporation” felt to be “key factors in HER-K113 loss
of replication capacity” [25].
Xq21.33, was recently discovered by mining whole
genome sequencing data (WGS) from the 1KGP. This
provirus had a sample wide allele frequency of 0.0157
(frequency of 0.026 to 0.069 in African populations)
mostly in Nigerian, Gambian, Kenyan and Pygmy popu-
lations [31]. This virus was also detected at low fre-
quency in African Americans from the southeastern
United States and persons living in the Caribbean, but
not in other African persons living in other parts of the
world. This virus has been estimated to have entered the
human genome about 0.67 to 1.3MYA [31]. It appears to
be fully intact and could potentially be activated. The
relative rarity, as well as the potential to replicate, made
this virus very intriguing to study to see if carriers of
Xq21.33 in African populations might be more likely to
develop BrC than non-carriers, and to understand the
evolution of this virus’ sequence in different areas of Af-
rica, and in African populations who were forced out of
Africa to America via the slave trade.
Methods
Study subjects, cell lines and DNA samples
Women with BrC provided a consent to participate in a
large study of BrC being carried out in Nigeria. These
women donated peripheral blood mononuclear cells
(PBL) for DNA analysis for genome wide association
studies (GWAS) as well as for whole genome sequencing
studies. Age matched controls, ages 19–82 years, in
neighboring clinics were also asked to participate in this
study. The study was conducted at the Institute of Hu-
man Virology Nigeria, an affiliate of the Institute of Hu-
man Virology, University of Maryland, Baltimore. DNA
from PBL from African American men with prostate
cancer was obtained from a large study of prostate can-
cer carried out at the University of Michigan.
DNA was extracted from saliva samples obtained dur-
ing clinic visits from women in Ghana or from African
American women in the United States with a history of
BrC .
Additional germline DNA from women with BrC in
the United States and patients with HIV and other disor-
ders was obtained from an earlier study of K111 virus in
health and disease [24].
BrC cell lines were obtained from a laboratory at the
University of Michigan that had all cell lines finger-
printed before use.
Cell lines from African American patients were ob-
tained by EJ and SM including breast cancer cell line
HCC70 (ATCC® CRL-2315™) [triple negative primary
ductal carcinoma], MDA MB157 (ATCC® HTB-24™) from
medullary carcinoma, MDA B 468 from a pleural effu-
sion, HCC1806 (ATCC® CRL-2335™) primary
acantholytic squamous cell carcinoma, SUM 149PT
from a xenograft of a transplanted primary explant of a
human invasive infiltrating duct carcinoma and ZR7530
(ATCC® CRL-1504™) from metastatic ductal carcinoma.
Cell lines were grown in media suggested by the com-
pany providing such lines. Other cell lines were estab-
lished in our laboratory from tumor biopsies obtained
from left over pathology samples. This material was ob-
tained with informed consent with the donor remaining
unknown but the pathology of the tumor known. This
protocol which allowed cultivation of cells was approved
by the University of Michigan Investigation Review
Board (IRB). This included cell lines 09–1521, 12–1697,
12–135, 13–1357, 14–130, 15–107. Cell lines K151 and
NSUH1 were established at North Shore University Hos-
pital, (NSUH) Manhasset N.Y., from pleural effusions
cells obtained with informed consent in a protocol ap-
proved by the NSUH IRB. These cells were grown in
RPMI 1640 with penicillin and streptomycin and 10%
heat inactivated calf serum.
DNA was extracted from PBL and cell lines using the
DNeasy blood and tissue kit™ and/or the Qiagen Gentra
Purgene® assay. Saliva was collected in the Oragene OG-
500 collection kits. DNA was extracted manually using
the prepIT-L2P DNA Genotek (catalog # PT-L2P).
Pathology
Women from Nigeria with BrC were clinically staged ac-
cording to the American Joint Committee on Cancer
system [33]. Immunohistochemistry of the primary tu-
mors was done with monoclonal antibodies for estrogen
receptor (ER), progesterone receptor (PR) and HER/
2neu (HER2) and Ki-67, EGFR and CK5/6 using mono-
clonal antibodies from Thermo Scientific™(clones ER-
SP1; PR-SP2; HER2-SP3) and Thermo Scientific™ Ultra-
vision™ Quanto Detection System HRP DAB detection
kit according to the manufacturers recommendations.
Polymerase chain reaction
PCR to search for Xq21.33 was carried out by
screening with the following primers:
Coff Xq21.33 ACG CTG TTT TGT CCC TTT GA.
1016 R CGTCGACTTGTCCTCAATGACCACGCT.
1584R TTTGCGTTGACTGAGCCATTACCG.
2477 R TTG AGC AAC ATC TTG GAG CCT TGC.
3456R ACT TGC CCA ATA TGC AGC CTT TCC
TCC.
6115R TCA ACT ATG GCC TGT CCT TGC GAA.
5355F TCG GCT CAA AGA GCA GAG ATG GTT.
F Flank TCAGTC TGA AGA CAA TGA CAT ACT T
T.
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Approximately 200 ng of DNA was tested with a primer
Coff Xq21.33 in the 5′ insertion site and any second pri-
mer (either 1016R, 1584R, 2477R, 3456R, or 6115R) lo-
cated in the Xq21.33 genome, and/or a 3′ insertion site
primer, F Flank (R) to 5355F in the virus. PCR was carried
out using the LongAmp® Taq PCR Kit (New England Bio
Labs). Reactions were carried using 5ul of 5X Long Amp
Taq reaction buffer + .75ul of 10uM DNTP, + 0.2 ul of
50uM forward and 0.2ul of 50uM reverse primer with
addition of 1ul of Long Amp Taq DNA polymerase plus
the addition of between 50 to 250 ng of sample DNA to a
final volume of 25ul. In general, the reactions were carried
out 94 °C initial denaturation for 30 s followed by 35 to 40
cycles of 94° for 15 to 30 s, 55° to 60° for 15 to 30 s and
65° for 2 to 5min, and then final extension at 65° for 10
min. All positive samples to 1011R to Coff Xq21.33 were
confirmed with at least 3 other primer sets.
Homozygosity was determined by using primers at
Xq21.33 and F Flank to obtain a PCR product of 420 bp
in heterozygotes and no amplification product in
homozygotes.
Genotyping of Xq21.33
Genotyping of the 3′ env region of Xq21.33 was carried
out by creating an amplified product using F Flank to
5355F using the protocol noted above. The amplified
product was resolved from 0.8% agarose gels and bands
of DNA of interest were cut from gels and purified using
the QIAquick Gel extraction kit QIAGEN according to
the method of the manufacturer. The purified product
was sent for direct sequencing to the DNA sequencing
core of the University of Michigan using primers in for-
ward or reverse orientation ranging from 5350 to 9472.
Phylogenetic analysis
Neighbor-Joining trees were generated using MEGA 7.
The evolutionary history was inferred using the
Neighbor-Joining method [34]. The percentage of repli-
cate trees in which the associated taxa clustered together
in the bootstrap test (1000 replicates) are shown next to
the branches [35]. The tree is drawn to scale, with
branch lengths in the same units as those of the evolu-
tionary distances used to infer the phylogenetic tree.
The evolutionary distances were computed using the
Maximum Composite Likelihood method [36] and are in
the units of the number of base substitutions per site.
The rate variation among sites was modeled with a
gamma distribution (shape parameter = 1). There were a
total of 3044 positions in the final dataset. Evolutionary
analyses were conducted in MEGA X [37].
Statistical analysis
Differences in the presence of the Xq21.33 provirus be-
tween cases and controls were examined using Fisher
exact tests All analyses were performed using Stata SE
version 15.1 (College Station, Texas). A type I error (α)
level of 0.05 was considered significant for testing the
study’s hypotheses. http://www.stata.com/support/faqs/
statistics/adjusted-means-after-anova.
Results
Two hundred thirty-nine Nigerian women with BrC par-
ticipated in this study. In 4 the DNA concentration was
too low for adequate use in PCR. In addition, in 19 con-
secutive samples there was an interfering substance
present which prevented PCR reactivity. These samples
were amplified multiple times with different primers to
get a signal, but they would not amplify. These patients
are not included in this study. This left 216 women with
breast cancer who became part of this study. There were
229 control women enrolled in the study. Of these, 10
had very poor DNA content. This left 219 control
women as part of this study.
Proviral DNA was screened for in all samples first
using the primer set 1016R and Coff Xq21.33. All posi-
tive samples were then screened with other primer sets
including 1584R, 2477R, 3456R and 6115R in conjunc-
tion with Coff Xq21.33. This covered the LTR and the
gag and pol genes of the provirus. In addition, we
screened positive samples for the env gene using 5359F
and F Flank. Representative positive samples are shown
in Fig. 1.
The Xq21.33 provirus was present in 27 of 216
(12.5%) Nigerian BrC cases compared to 22 of 219
(10.0%) controls These results were not statistically
different.
Table 1 presents the study participants by age groups
and by virus status. We did not have accurate ages on all
women. In those with ages specified, as seen in Table 2,
in women with BrC who were 44 years and younger
(presumed to be premenopausal) the virus was found in
12 of 117 (10.3%), while it was in 18 of 157 (11.5%) con-
trol women under age 44 years. Interestingly, this differ-
ence breaks apart in women older than 44 years
(presumed to be postmenopausal), 15/98 (15.3%) women
with BrC were virus positive while in women without
BrC only 4/54 (7.4%) were virus positive. This difference
was not statistically significant at the .05 level; the p-
value was (0.079), but is suggestive of a trend that may
warrant further exploration if the sample size of older
women was higher.
We used this age 45 or greater as presumed post-
menopausal age as we have broken our data into age
groups at 5 years intervals. In Nigeria the average age
of menopause is 48.4 +/− 5 years (samples size n = 563
age range 44–87) [38], and in Ghana the average age
of menopause is 48.4+/− 3.62 (sample size n = 123 age
range 40–56) [39].
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We next looked at DNA from patients in the United
States who had BrC and other conditions (Table 2). Of
note, 10/113 (8.8%) African Americans were virus posi-
tive. Of these 6/51 (11.8%) were women with BrC, 3/42
men with prostate cancer, 1/3 men and 0/8 women with
HIV having virus and 0/9 persons with other cancers.
No Caucasian American patients had virus, (n = 109)
confirming previous observations reporting the specific
incidence of Xq21.33 in in people with African ancestry
[31]. We also screened buccal swabs collected from pa-
tients from Ghana. 6/87 (6.9%) had provirus in contrast
to 49/439 (11.2%)in Nigeria and 1/6 (16.6%) among Pyg-
mies from the Congo basin.
We looked to see if there was homozygosity/hemizogo-
city for this virus in women with BrC and virus vs those
without breast cancer and provirus. An illustrative PCR
gel is shown in Fig. 2. We found that 5/27 (18%) women
with breast cancer were homozygous for provirus while
2/22 (9%) women without breast cancer and provirus
were homozygous. This was not statistically significant.
We were particularly interested in seeing if the path-
ology of BrC was different in women who had the virus
and those who were negative. Extensive biomarkers were
carried out on the Nigerian cohort of women as shown
in Table 3. As can be seen there was no distinguishing
difference in the biomarker status between the patients
who were virus negative vs those who were virus posi-
tive. Triple negative BrC was rather common in this
population occurring in 49/156 cases (31.4%). The ages
of women who were triple negative were not different
from those who had other hormonal markers tested.
We also screened known cell lines for the presence of
Xq21.33 proviruses as shown in Table 4. Two of these
28 cell lines, 2 (DT 22 and HCC70) were established
from triple negative BrC arising in African women. Rep-
resentative screening for the virus is shown in Fig. 3.
We did genomic sequencing in order to determine if
there is variation in the Xq21.33 sequence in populations
from West Africa. Mutations found from PCR product
amplified from primers 5355F to F Flank giving a se-
quence spanning the env region of the virus are shown
in Table 5. Two sets of complete sequences spanned
long regions. In one set we sequenced from approxi-
mately 5390 to 9472 and in a second set we extended
this from approximately 5355 to 9472. In a third set we
could not get complete sequences and had areas of ap-
proximately 50–150 bp long which lacked adequate se-
quences. Using 30 complete sequences from 5355 to
9472, all had a common mutation of 5370 T to A, and
both sets of complete sequences (total 46) had a
Fig. 1 This shows the PCR product from amplifying the DNA of the Xq21.33 proviruses from two Nigerian women without breast cancer (labeled
N) and two women with breast cancer (labeled P). The primers sets were CoffXq21.33 to 3 reverse primers noted and one set from 5355F to F
Flank which spans the env region of the provirus
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mutation of 8529 A to G. Twenty five of 46 samples
(54.3%) had a mutation of 7596 T to C when compared
to the deposited sequence KU054272.1. Samples from
Nigerians, Ghanaians and African Americans had these
same 3 mutations. The two cell lines DT22 had HCC70
both had the 5370 and 8529 mutation present, while
DT22 also had a 7596 mutation. The 5370 or 8529 may
be true SNPs, but also may just represent an error in the
original sequence. There were 2 Nigerian and 2 Ghan-
aian sequences found with both having the 5370, 8529
Table 1 Prevalence of Xq21.33 Detection in African Women with or without Breast Cancer
Age BrC
No Xq21.33
BrC Xq21.33 No BrC
No Xq21.33
No BrC Xq21.33 (chi square test, p value)
15–19 0 0 1 0
20–24 2 0 3 1
25–29 12 0 25 3
30–34 17 4 31 5
35–39 38 4 38 4
40–44 36 4 41 5
Total pre-menopausal 105 12 139 18 X2 = 0.100
p < 0.3757 (ns)
45–49 23 3 26 3
50–54 27 8 8 0
55–59 16 2 11 1
60–64 7 1 5 0
65–69 6 0 0 0
70–74 1 0 0 0
75–79 3 0 0 0
80–84 0 0 0 0
85–89 0 1 0 0
Total post-menopausal 83 15 50 4 X2 = 1.986
p < 0.079 (ns)
Age unknown 1 8
Total 189 27 197 22
Detection of HK2 Xq21.33 provirus in the DNA of BrC and control women (No BrC) in populations from African ancestry. The P values show the statistical
significance difference of Xq21.33 virus detection between pre-menopausal and post-menopausal women with and without BrC. The statistical test Chi-square
without Yates correction was used. The X2 and p values are indicated. There is no statistical difference between the prevalence of Xq21.33 in the pre-menopausal
women but the prevalence of Xq21.33 in post-menopausal women is approximately double that in women without breast cancer but this is also not statistically
different at a p value of <.05
Table 2 Prevalence of Xq21.33 in different populations
Caucasian African African American (chi square test, p value)
BrC 0/95
No BrC 0/8 0/9
Ghana BRC 6/87
Nigeria BrC + no BRC 49/435
Pygmy 1/6
African American BrC (women) 6/51
African American aPCa (men) 3/42
HIV+ 0/6 1/3(men) 0/8 women
Total 0/109 (0%) 56/528 (10.6) 10/113 (8.8%%)
aPCA Prostate Cancer
Detection of HERV-K HML-2 Xq21.33 virus in the DNA of populations from African and Caucasian ancestry. The P values shows the statistical significance
difference of Xq21.33 virus detection between Caucasian individuals and population from African ancestry. The statistical test Chi-square without Yates correction
was used. The X2 and p values are indicated. Caucasian Vs African, (X2 = 16.094, p < 0.0001). Caucasian Vs African American, (X2 = 14.959, p < 0.0001)
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Fig. 2 Panel a shows a representative agarose gel to detect homozygocity or hemizygocity in African female individuals with BrC and HERV-K
HML-2 Xq21.33 virus. Amplicons from DNA from some women with BrC (#P) and a normal Gambian person are shown which were obtained
using a primer in the preintegration region of Xq21.33 on the 5′ side of the virus (CoffXq21.33) and a primer on the 3′ side of the integration site
(F Flank). Homozygotes would not give a product as the 9472 bp virus present in both chromosomes X will not allow amplification using this
protocol whereas hemizogous (having HERV-K HML-2 Xq21.33 in only one chromosome X) would give a 480 bp product corresponding to the
empty preintegration site of one chromosome X. Panel b shows a male K344 who has HIV lymphoma and has the Xq21.33 virus present. This
virus is only in his X chromosome while his y chromosome has no virus. His DNA would not give a 480 bp amplicon using this same protocol. A
patient with breast cancer who is hemizygous is shown in the 1st lane next to the molecular weight markers
Table 3 Hormone Receptor Status in Breast cancer specimens
Virus Negative Average Age Virus Positive Average Age
Not done 51 43.2 5 43.8
ER-, Pr-, Her2Neu- 43 46.4 6 43.8
ER+, PR+ Her2Neu- 25 45.3 4 59
ER+, PR+, ER2Neu+ 11 40.9 1 38
ER+, Pr-, HER2Neu- 17 45.1 2 40.5
ER+, Pr-, HER2NEU+ 3 43.6 0 N/A
ER-, PR- HER2Neu+ 12 45.9 4 49
ER-, PR+, HER2Neu- 6 48.2 1 52
ER-, PR-,HER2Neu ND 4 34.5 2 34
ER-. PR+, HER2Neu+ 1 28 1 58
ER+, PR ND, HER2NEU ND 6 45.2 0 N/A
Other 6 44.5 1 52
In the virus positive group 3/27 are read as Ductal Carcinoma in situ
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and or the 7596, while other mutations were found as
shown in Table 5.
Genetic sequences were compared to the known
HERV-K HML2 sequences to understand the evolution
of Xq21.33 and how 2 Nigerians and 2 Ghanaians had
more than 3 SNPs present. All proviruses had the 5370
and 8529 mutation, which may have existed in the
founder virus, while about 54.3% of proviruses had an
additional mutation at 7596. All mutations preserved the
integrity of the env protein.
We performed a phylogenetic analysis to understand
the evolution of HERV-K HML-2 sequences isolated in
Nigerian and Ghanaian populations. A Neighbor-Joining
tree shows that genetic mutations and possible gene
conversion events occurred during HERV-K HML-2
Xq21.33 evolution (Fig. 4). Placing Xq21.33 reference se-
quence as the ancestral sequence, the tree revealed two
different features. First, a genetic mutation (T > C) of
Xq21.33 appeared in sequences of Nigerian and Pigmy
populations in West-Central Africa, but also in all se-
quences obtained from Ghana (West Africa) (Supple-
mentary Fig. 1). This suggests that the spread of this
mutation may have occurred from the migration of indi-
viduals in this area of Africa. The tree also shows two
Nigerian and two Ghanaian individuals (NoB1, NB2,
GB1 and GB2 respectively) who have additional muta-
tions, (Supplementary Fig. 1) likely originated by gene
conversion between Xq21.33 and other HERV-K HML-
2s. These HERV-K HML-2 mutations were found in
HERV-K HML-2s in other chromosomal locations. The
divergence between HERV-K HML-2 Xq21.33 sequences
in African populations appears to indicate that these
events happened relatively recently in human evolution.
Further evidence of gene conversion may be a result of
copying HERV-K HML-2 Xq21.33 from one X chromo-
some to the other. Although it is possible that the
Table 4 Detection of Xq21.33 in Cell lines
Cell Line Xq21.33 Ethnicity Cell Type Gender
HCC70 + Black Primary duct cancer female
DT22 + Black Triple negative female
MCF7 – Caucasian Adenocarcinoma breast female
T47D – unknown Metastatic pleural effusion female
SKBr3 – Caucasian Invasive duct cancer female
K151 – Caucasian Invasive duct cancer female
BT474 – Caucasian Invasive duct cancer female
HUS78 – unknown unknown
MDA MB453 – Caucasian Adenocarcinoma breast metastatic pleural effusion female
MDAMB 157 – Black Medullary carcinoma breast female
MDA MB468 – Black Adenocarcinoma pleural space (breast) female
HCC 1806 – Black acantholytic squamous cell carcinoma breast female
SUM149 – NA Triple negative Invasive duct BrC Female
ZR7530 – Black Invasive duct BrC female
JURKAT tAT – unknown acute T lymphoblastic leukemia male
DHL1 – unknown Diffuse large cell lymphoma cell line from pleural effusion male
HL60 – Caucasian Acute promyelocytic leukemia female
HUT 78 Caucasian Cutaneous T cell lymphoma male
H9 – Caucasian Derivative of HUT 78 male
SupT1 – Caucasian T lymphoblastic lymphoma unknown
MT4 – unknown Adult T acute lymphoblastic leukemia male
09–1521 – unknown EBV+ B cell from follicular lymphoma unknown
12–1697 – unknown EBV + B cell from lymphoma unknown
12–135 – unknown EBV negative cell line from marginal zone lymphoma unknown
13–1357 – unknown EBV negative cell line from Hodgkin lymphoma unknown
14–130 – unknown EBV+ cells from follicular lymphoma unknown
15–107 – unknown EBV - cells from transplant lymphoma unknown
NSUH1 – Caucasian EBV – cells from diffuse large B cell lymphoma male
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appearance of homozygous inherited HERV-K HML-2
Xq21.33 may have come from both parents, this prob-
ability is very small, considering the rare frequency of
Xq21.33, which in these screened populations in Africa
was 10–12% in women and probably much lower in
men. This would make the predicted homozygous state
to be less than 1%, whereas in these females the preva-
lence of being homozygous was 24%, which is more
likely the ¼ chance that can occur during meiotic re-
combination. Therefore, it is more likely one HERV-K
HML-2 Xq21.33 virus copied to the other chromosome
X during meiosis by gene conversion.
Discussion
To date studies of endogenous retroviruses have been
trying to determine if any of these proviruses can be ac-
tivated again to produce infectious virions which may
genetically alter cells and lead to a disease process. Thus
far no provirus has been convincingly associated with a
disease. Great interest has been placed on seeing if any
or some HERV-K HML-2 viruses can be linked to BrC,
as these viruses are genetically distantly related to
Fig. 3 Detection of HERV-K HML-2 Xq21.33 in cell lines and African male descendants. This shows the products of amplification of DNA from two
Breast cancer cell lines HCC70 and DT22 and K344 from an African American man with HIV associated lymphoma and an African American man
with prostate cancer. The primer sets used march the genome of Xq21.33 using Coff Xq21.33 F to 1584 R, 2477R, 3456R and 6115R and another
primer set 5355F to F Flank. The laddered bands represent the appropriate amplicon for these primers. Note that the 6115R to Coff Xq21.33
did not amplify as it is often difficult to produce a product because of the large size of the amplicon. A nonspecific amplicon is seen in
the 6115 lane
Table 5 Mutations in the env region of HERV-K HML-2 Xq21.33
(Acc. No. KU054272.1)
Possible first conversion events
5370 T to A Nigerian, Ghanaian, African Americans, Pygmy
Cell line HCC (found in complete sequences from 5355 to 9472)
30/
30
8529 A to G Nigerian, Ghanaian, African Americans, Pygmy
Cell line HCC and DT22 (found in complete sequences from 5355
to 9472 and from about 5390 to 9472)
46/
46
7596 T to C Nigerian, Ghanaian, African Americans, Pygmy
Cell line DT22 only
25/
46
Possible second conversion events
Nigerians only
5370, 8529 and 7596 +
5735 C to T, 6089 C to T, 6345 C to T 7274 A to G, 7795 G to A,
8914 T to C
2/2
Ghanaians only
5370, 8529 and 7596 +
6914 C to T, 7203 G to A, 8170 A to G, 8600 C to A
2/2
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MMTV. Early studies of BrC cell lines revealed the pres-
ence of viral particles possibly related to HERV-K HML-
2. The T47D cell line grown from a neoplastic pleural
effusion was shown to produce viral particles when stim-
ulated first with estradiol and then progesterone [40]. At
first these particles were thought to be more related to
MMTV [40–42]. Further studies of the T47D cell lines
[43, 44] and cells grown from BrC pleural effusions [45]
further suggested that a similar MMTV-like virus called
HMTV was seen in such cell cultures [45]. Later it was
felt these were more likely related to HERV-K HML-2
proviruses [46].
Attempts were made to determine if HERV-K HML-2
proteins might appear in BrC cell lines or tumors.
Fig. 4 Evolution of HERV-K HML-2 Xq21.33 in Africa. Evolutionary relationships of taxa. The evolutionary history was inferred using the Neighbor-
Joining method [34]. The optimal tree with the sum of branch length = 0.00263695 is shown. The percentage of replicate trees in which the
associated taxa clustered together in the bootstrap test (1000 replicates) are shown next to the branches [35]. The tree is drawn to scale, with
branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were
computed using the Maximum Composite Likelihood method [37] and are in the units of the number of base substitutions per site. The rate
variation among sites was modeled with a gamma distribution (shape parameter = 1). This analysis involved 42 nucleotide sequences. Codon
positions included were 1st + 2nd + 3rd + Noncoding. All ambiguous positions were removed for each sequence pair (pairwise deletion option).
There were a total of 3044 positions in the final dataset. Evolutionary analyses were conducted in MEGA X [36]. The tree is rooted to the known
Xq21.33 HERV-K HML-2 sequence (Accession no. KU054272.1). NB: Nigerian BrC, NoB: Nigerian No BrC, AAP: African American PCa, P: Pygmy, GB:
Ghanaian BrC, DT22: African BrC cell line. The left side of the tree would indicate a first genetic drift (T > C) event and at the right side the three
show two small protruded branches that indicate gene conversion events
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Indeed NP9, a 9 kb protein expressed predominantly in
the nucleus as a product of Type 1 HERV-K HML-2
proviruses, was described by Armbruester et al. [47].
This protein was found in 4 BrC cell lines, (T47D,
MCF7, MDA-MB231 and SKBr), as well as in 52% of
BrC tumors. Transcripts of HERV-K HML-2, mostly
from type 1 proviruses, could also be detected in most
BrC cell lines and tumors [48]. Type 2 transcripts which
might express the envelope of HERV-K HML-2 were
also found, [49] and in different cell lines hormonal
stimulation increased the mRNA expression of HERV-K
HML-2 transcripts. Similarly, increased expression of
HERV-K HML-2 was reported as high as 70% of tumors.
Both type 1 and type 2 transcripts were seen. Monoclo-
nal antibodies were prepared to the recombinant fusion
protein K10Q18, which resulted in a monoclonal anti-
body with great affinity for the K SU, which is a 55-kDa
surface subunit of HERV-K HML-2 rather than the 39-
kDa transmembrane subunit env surface protein [50].
Eighty-five percent (85%) of invasive ductal carcinoma
(IDC) biopsies showed expression of this protein, while
only 28.57% of normal breast tissue and/or hyperplastic
breast tissue showed such protein expression. Most of
the protein was expressed in the cancer tissues [51].
Antibodies to the SU protein, using immunoprecipita-
tion and enzyme linked immunosorbent assay (ELISA)
technology, were seen in 50% of samples, some with ra-
ther high titers. Only low titers of antibody were seen in
normal controls, suggesting that antibody levels might
be associated with cancer progression. However, a differ-
ent study of antibodies to the SU fragment failed to
show any distinguishing antibody response between nor-
mal tissue and BrC cells [52]. Various immunoassays, in-
cluding Interferon γ (IFN-γ) ELISPOT assays, revealed
“that PBMCs from BrC patients contain HERV-K spe-
cific cytotoxic lymphocytes (CTL) that can be re-
stimulated in vitro to induce detectable cytolytic activity
against HERV-K expressing targets” [51]. Similarly, these
same PBMCs from BrC patients showed HERV-K HML-
2 specific cytokine secretion against HKL2 target cells.
In addition, “anti HERV-K specific monoclonal anti-
bodies inhibited growth and induced apoptosis of BrC
cells in vitro” in a mouse xenograft model using different
cell lines [53]. Human tumors showing more expression
of HERV-K HML-2 SU antigen on their surface were
more likely to have metastatic potential. Further studies
showed again that there was high expression of env pro-
tein on tumors of both American and Chinese patients,
and the level of expression correlated with poor progno-
sis [54]. Using The Cancer Genome Atlas (TCGA) RNA
Seq-database to evaluate the “expression of the HERV-K
108 (7p22.1), HERV-K 109 (6q14.1) HERV-K 113
(19p12b) and HERV-K 115 (8q23.1) loci in basal,
HER2E, LumA and LumB breast cancer subtypes”, it
was found that in 512 patients, HERV-K HML-2 from
these 4 different loci were more highly overexpressed in
this type of BrC [55]. Subsequent studies showed that
activation of HERV-K env was necessary for metastasis
and tumorigenesis of BrC cells [56].
Other studies have looked to see if H2K proviruses are
involved in transcription during transformation of mam-
mary epithelial cell to neoplastic cells. This was accom-
plished by taking human mammary epithelial cells and
immortalizing them through telomere maintenance by
“hTert” (encoding human telomerase reverse transcrip-
tion) over expression. These cells were then transformed
with SV40 small and large T antigen, and then further
transformed with a murine leukemia virus (MLV) base
vector. This led to over expression of the BrC oncogene
HRAS (V12) and/or ERB2 (Her2/neu). These cells were
then looked at to see what mRNAs were used that be-
long to the HERV-K HML-2 group. Surprisingly, the
HML2 transcriptome analyzed showed that most of
transcription arose from 15 HML2 proviruses. The ma-
jority of transcription was in an antisense orientation
and “from mostly older proviruses integrated within in-
trons” [57]. Viruses that transcribed mRNA in a sense
orientation did not produce transcripts that could make
any proteins, which is contrary to what has been de-
scribed in BrC cell lines and even in tumors themselves.
With all of this analysis so far, it still remains unclear
if there is a specific HERV-K HML-2 provirus associated
with BrC and/or how activation of HERV-K HML-2
might be playing a role in formation of BrC. With the
discovery of the new Xq21.33 provirus [31], which ap-
pears to be present in limited populations only in Africa,
and mostly in Nigeria and Gambia and in Pygmy popu-
lations, it seemed that a study of BrC arising in patients
carrying Xq21.33 could provide insight into whether
having this provirus might predispose a person to BrC,
especially as the Xq21.33 virus is fully able to make all
viral proteins. We thus embarked on this study of
women with BrC in Nigeria and compared the preva-
lence of this provirus to a control group of women with-
out BrC. We also studied the distribution of this virus in
other areas of Africa and the United States.
In Nigerian women the prevalence of this virus is
higher (49/444 women 11.03%) than that detected by
Wildschutte et al. (6.9%) [31]. This difference may occur
because we had more persons to test, and their data was
from the 1KGP which has a very different sampling
method. We show that this provirus is present not only
in Nigerian populations, but also in Ghanaian women,
Pygmy people from Gambia, and not surprisingly, also
in African American men and women (10/113 8.8%)
whose heritage dates back to these countries.
This provirus has not spread as widely as younger pro-
viruses K113 or K115, which have been reported to be
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present in 21.8 and 34.1% of African populations [28].
For instance, sequence analysis shows that Xq21.33 is
likely younger than K113 and K115, and a single muta-
tion (T > C, base 7596) can predict to some degree hu-
man migration from Central to West Africa 100,000 to
200,000 years ago. Then, it appears that Xq21.33 is the
youngest HERV-K HML-2 virus in humans. In addition,
the Xq21.33 viral sequence incorporates few additional
mutations by gene conversion, likely due to its
localization in Chromosome X, where it can exchange
material with the complementary X chromosomes dur-
ing meiosis. Finding signatures of Xq21.33 from HERV-
K HML-2 residing in other chromosomes also suggest
that Chromosome X HERV-K HML-2 may exchange
material with other somatic chromosomes, although at a
low rate. Considering the young age and active sequence
area in Chromosome X, it is possible that Xq21.33 pro-
duces some level of increased morbidity and mortality in
those who have virus, which hinders the spread of virus
over the generations.
These SNPs found in HERV-K HML-2 Xq21.33 do
not create stop codons in the viral env region but might
modify the biology of the provirus. Several samples have
multiple SNPs which, on genetic analysis, suggests some
form of gene conversion occurring in some Nigerians
and some Ghanaians. The mutations we found cannot
be explained by PCR artifact which would produce many
random mutations, rather than those seen. This would
suggest that Xq21.33 is in a hot spot of the genome,
which may allow for some recombination with other ac-
tive viruses, such as K113.
There was no difference in the prevalence of virus be-
tween those women with BrC and women without BrC
indicating that this virus does not play an active role in
breast carcinogenesis. In an unplanned analysis by
menopausal state if one divides these patients into pre
and post-menopausal groups, then virus is more preva-
lent in post-menopausal women, rising from 12/117 or
10.25% to 15/98 or 15.30% in women with BrC while
falling from 18/157 or 11.4% to 4/54 or 7.4% in post-
menopausal women without BrC. This difference in fre-
quency of provirus in post-menopausal women is not
statistically significant at the 0.05 level as the study was
not powered to detect such small differences, should
they be relevant to the process or carcinogenesis, but is
closer to the 0.079 level. It is clear that our sample size
is too small. Clearly an adequately powered study of
post-menopausal women might be undertaken to ex-
plore a potential significant association of this virus in
post-menopausal African and or African American
women with BrC.
We did see a higher prevalence of triple negative BrC, as
has been reported earlier in patients from Africa. Our pa-
tients are relatively younger than patients with BrC in
Europe and the Americas. This may be more due to the
fact that the average life span of women living in Nigeria,
according to the World Health Organization, is about 54.7
compared to that in the United States, Germany, Sweden
and the United Kingdom, which is about 81.0, years of
age. As health is improving in Nigeria the percentage of
triple negative BrC may reduce, as older women are less
likely to have triple negative cancers.
In order to understand the potential role of this virus
even if our study, or a future larger study with more
post-menopausal women, had shown a statistically rele-
vant association of Xq21.33 in post-menopausal BrC, it
would still be necessary to show that this provirus has
activated and is now in some area in the BrC cell differ-
ent from Xq21.33 and the known HERV-K HML-2 inte-
gration sites and in a genomic area where it might
disrupt some cellular growth factor. Such a virus would
also have to be able to infect breast tissue. Recently it
has been shown that the HERV-K HML-2 env gene from
the artificially constructed Phoenix virus, [58] encoded
in a vesicular stomatitis virus, will bind to heparan sul-
fate molecules which are universally present on many
cells [59]. It was also shown that an Xq21.33 env con-
struct similarly binds to heparan sulfate [59]. Heparin
sulfate binding sites are common on many cells. If there
is an infectious HERV-K HML-2, then it could readily
infect a person exogenously through skin and/or via
blood exposure, or it could activate from the genome.
Since cells have 117 proviruses present, as well as over
2000 LTRs and over 1000 pericentromeric and centro-
meric HERV-K HML-2 s, all of which are almost 97–
99% the same, using current platforms for sequencing to
detect provirus would be very difficult as a newly inte-
grated provirus would be obscured by such background
noise. One would have to find sequences that are within
a new area of the genome and or repetitive elements in
the centromeric regions. Such a sequence would have to
span the full LTR and extend into the sequence of the
virus itself. Current sequencing provides only fragments
of 300–400 bp, which are not of sufficient length, or
number, to distinguish virus from background HERV-K
genomes and LTRs. However, if virus did get to the
breast and integrate in an area to induce an oncogenic
change, virus would be amplified many fold by the clonal
expansion induced by the cancer. This new insertion site
in the cancerous breast tissue could only be detected by
sequencing larger portions of the genome with new
available technologies that give long sequence reads.
Similar technology has been used in a study of large
granular cell leukemia thought to be due to a HERV-K
HML-2 virus. While this study could not confirm the
presence of a HERV-K-HML-2 virus it does provide
insight into how such technology can be used in cancer-
ous cells [60].
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Conclusion
We searched for evidence that a recently discovered
HERV K HML-2 virus Xq21.33 might play a role in pre-
disposing women to BrC in those carrying this provirus.
Our data describes some of the genetic variation in this
provirus but our data could not support an association
of Xq21.33 with breast cancer. However, it does suggest
that there may be some role for this provirus in predis-
posing post-menopausal women carrying this virus to
breast cancer which could be discovered if a more ap-
propriate sample size of older patients was studied. Find-
ing of such an association would be important as
antiretroviral drugs might be useful in preventing BrC in
such women.
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